文献速递血管炎

ShK186阻断Kv1.3对肉芽肿性多血管炎患者CD4+效应记忆T细胞活性的调节作用

Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

本研究为体外研究,纳入27例缓解期肉芽肿性多血管炎(GPA)患者和16例年龄性别匹配的健康对照,外周血样本经ShK-186预孵育后刺激,用流式细胞术检测CD4+辅助T细胞各亚群细胞因子产生。结果显示ShK-186在体外降低GPA患者CD4+TH细胞中IFNγ、TNFα、IL-4、IL-17和IL-21表达,主要抑制CD4+效应记忆T细胞(TEM)的细胞因子产生,并降至健康对照水平。作者认为通过ShK-186调节细胞效应功能可能构成GPA的新型治疗策略。

要点

  • ShK-186在体外降低GPA患者CD4+TH细胞中IFNγ、TNFα、IL-4、IL-17和IL-21的表达水平。
  • ShK-186主要抑制CD4+效应记忆T细胞(TEM)的细胞因子产生。
  • ShK-186使促炎细胞因子产生降至健康对照CD4+TH细胞中所见水平。

核心结论

  • 通过ShK-186调节细胞效应功能可能构成GPA的一种新型治疗策略,具有高特异性和较少有害副作用。

研究设计与样本

  • 体外研究,纳入27例缓解期GPA患者和16例年龄、性别匹配的健康对照(HCs),外周血样本在体外有或无ShK-186预孵育后,经佛波醇肉豆蔻酸乙酸酯、钙离子载体和布雷菲德菌素A刺激,用流式细胞术评估ShK-186对CD4+辅助T(CD4+TH)细胞总数及亚群内细胞因子产生(IFNγ、TNFα、IL-4、IL-17、IL-21)的影响。

主要发现

  • ShK-186在体外降低GPA患者CD4+TH细胞中IFNγ、TNFα、IL-4、IL-17和IL-21的表达水平。
  • 对分选CD4+T细胞亚群的进一步分析显示,ShK-186主要抑制CD4+效应记忆T细胞(TEM)的细胞因子产生。
  • ShK-186处理使促炎细胞因子产生降至健康对照CD4+TH细胞中所见的水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Granulomatosis with polyangiitis (GPA) is a chronic relapsing systemic autoimmune vasculitis. Current treatment of GPA is unsatisfactory, as it relies on strong immunosuppressive regimens, with either CYC or rituximab, which reduce the immunogenicity of several vaccines and are risk factors for a severe form of COVID-19. This emphasizes the need to identify new drug targets and to develop treatment strategies with less harmful side effects. Since CD4+ effector memory T cells (TEM) play a key role in the pathogenesis of GPA, we aimed in this study to modulate CD4+TEM cell activity via Kv1.3 blockade using the specific peptide inhibiter, ShK-186. METHODS: Peripheral blood samples from 27 patients with GPA in remission and 16 age- and sex-matched healthy controls (HCs) were pre-incubated in vitro in the presence or absence of ShK-186, followed by stimulation with phorbol myristate acetate, calcium ionophore and brefeldin-A. The effect of ShK-186 on the cytokine production (IFNγ, TNFα, IL-4, IL-17, IL-21) within total and subsets of CD4+ T helper (CD4+TH) cells were assessed using flow cytometry. RESULTS: ShK-186 reduced the expression level of IFNγ, TNFα, IL-4, IL-17 and IL-21 in CD4+TH cells from patients with GPA in vitro. Further analysis performed on sorted CD4+T cell subsets, revealed that ShK-186 predominantly inhibited the cytokine production of CD4+TEM cells. ShK-186 treatment reduced the production of the pro-inflammatory cytokines to the level seen in CD4+ TH cells from HCs. CONCLUSIONS: Modulation of cellular effector function by ShK-186 may constitute a novel treatment strategy for GPA with high specificity and less harmful side effects.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lintermans LL, Stegeman CA, Muñoz-Elías EJ, et al. Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2024. PMID: 37086441. doi:10.1093/rheumatology/kead192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。